Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases

Autor: Bartsch R; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Berghoff AS; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Furtner J; Department of Radiology, Medical University of Vienna, Vienna, Austria.; Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria., Marhold M; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Bergen ES; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Roider-Schur S; Department of Oncology, St. Joseph's Hospital, Vienna, Austria., Mair MJ; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Starzer AM; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Forstner H; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Rottenmanner B; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Aretin MB; Hospital Pharmacy, Vienna General Hospital and Medical University of Vienna, Vienna, Austria., Dieckmann K; Department of Radio-Oncology, Medical University of Vienna, Vienna, Austria., Bago-Horvath Z; Department of Pathology, Medical University of Vienna, Vienna, Austria., Haslacher H; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria., Widhalm G; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria., Ilhan-Mutlu A; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Minichsdorfer C; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Fuereder T; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Szekeres T; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria., Oehler L; Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria., Gruenberger B; Department of Oncology, LKH Wiener Neustadt, Wiener Neustadt, Austria., Pfeiler G; Department of Obstetrics and Gynaecology, Medical University of Vienna, Vienna, Austria., Singer C; Department of Obstetrics and Gynaecology, Medical University of Vienna, Vienna, Austria., Weltermann A; Department of Medicine 1, Elisabethinen Hospital Linz, Ordensklinikum Linz, Linz, Austria., Berchtold L; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.; Institute of Medical Statistics, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria., Preusser M; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.

Publikováno v: Neuro-oncology [Neuro Oncol] 2024 Jul 04. Date of Electronic Publication: 2024 Jul 04.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

281MO Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan: Secondary endpoint analysis of the prospective single-arm phase II TUXEDO-1 trial

Autor: Starzer, A.M., Berghoff, A.S.S., Furtner, J., Marhold, M., Bergen, E.S., Roider-Schur, S., Forstner, H., Rottenmanner, B., Dieckmann, K., Bago-Horvath, Z., Widhalm, G., Ilhan-Mutlu, A., Minichsdorfer, C., Fuereder, T., Gruenberger, B., Singer, C., Weltermann, A., R. Puhr, Preusser, M., Bartsch, R.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S668-S668

280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial

Autor: Bartsch, R., Berghoff, A.S., Furtner, J., Bergen, E.S., Roider-Schur, S., Marhold, M., Starzer, A.M., Forstner, H., Rottenmanner, B., Dieckmann, K., Bago-Horvath, Z.A., Widhalm, G., Ilhan-Mutlu, A., Minichsdorfer, C., Fuereder, T., Singer, C.F., Weltermann, A., Preusser, M.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S486-S486